Pharmaceutical Cost Cutting Seen Hurting Drug Quality
This article was originally published in The Gold Sheet
Executive Summary
FDA and industry officials say that the current cost-cutting environment is having a negative impact on drug quality, as evident by the record number of drug shortages and recalls. Such cost-cutting, they argue, is shortsighted and not worth the risks of losing jobs or going bankrupt, while investing in PAT and automation may help turn things around.